FDMT — 4D Molecular Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650648 ·
Last close
$8.71
Market Cap
$455.33M
52W High
$11.21
52W Low
$7.96
ADV30
666,662
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,047,000 | — | -73,620,000 | -68,760,000 | 512,905,000 | 72,488,000 | 61,069,000 |
| Dec 2025 | 85,090,000 | — | 14,715,000 | 19,397,000 | 566,711,000 | 60,241,000 | 61,047,000 |
| Sep 2025 | 90,000 | — | -61,185,000 | -56,876,000 | 423,982,000 | 48,555,000 | 54,999,000 |
| Jun 2025 | 15,000 | — | -59,456,000 | -54,658,000 | 473,637,000 | 77,159,000 | 52,747,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,082,000
Investing CF
$-92,973,000
Financing CF
$112,960,000
CapEx
$-3,424,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.64
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-716,304,000
Inventory
—
Receivables
—
ST Investments
$342,414,000
EBIT TTM
$-159,547,000
Pretax Income TTM
$-140,109,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$88,242,000
EBITDA
$-171,434,000
Free Cash Flow
$-69,357,248
Enterprise Value
$79,218,784
Total Cash
$390,892,000
Total Debt
$20,535,000
Shares Out
52,276,254
Trailing EPS
$-2.57
Book Value
$8.64
ROE
-34.9%
ROA
-21.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 85,209,000 | -159,547,000 | -140,109,000 | 566,711,000 | 61,047,000 | — | -109,082,000 |
| Dec 2024 | 37,000 | -187,841,000 | -160,868,000 | 560,384,000 | 49,778,000 | — | -134,585,000 |
| Dec 2023 | 20,723,000 | -112,867,000 | -100,837,000 | 339,891,000 | 32,062,000 | — | -75,792,000 |
| Dec 2022 | 3,129,000 | -110,032,000 | -107,494,000 | 261,846,000 | 30,509,000 | — | -86,685,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.72
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STRO | SUTRO BIOPHARMA, INC. | $453.70M | $27.38 | — |
| OCGN | Ocugen, Inc. | $453.62M | $1.34 | — |
| AUTL | Autolus Therapeutics plc | $447.12M | $1.68 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $463.71M | $8.69 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.60M | $5.14 | — |
News headlines (Yahoo Finance, 1h cache)
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
2026-05-20 12:36 · Yahoo
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
2026-05-17 00:02 · Yahoo
4DMT Announces New Employment Inducement Grants
2026-05-15 20:05 · Yahoo
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
2026-05-11 14:04 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 23:05 · Yahoo
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
2026-05-07 20:05 · Yahoo
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 12:50 · Yahoo
4DMT to Participate in Upcoming Investor Conferences
2026-05-04 12:00 · Yahoo
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
2026-04-10 13:57 · Yahoo
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
2026-03-18 21:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.